AngioDynamics Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AngioDynamics in the last year. There are currently 2 hold ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AngioDynamics stock.
View analyst ratings for AngioDynamics or view top-rated stocks.

Wall Street analysts have given AngioDynamics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but AngioDynamics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

AngioDynamics is scheduled to release its next quarterly earnings announcement on Thursday, September 30th 2021.
View our earnings forecast for AngioDynamics.

AngioDynamics will be holding an earnings conference call on Thursday, September 30th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 412-317-6671 with passcode "13723182".

AngioDynamics, Inc. (NASDAQ:ANGO) released its earnings results on Monday, March, 29th. The medical instruments supplier reported $0.02 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.02) by $0.04. The medical instruments supplier earned $71.18 million during the quarter, compared to the consensus estimate of $68.42 million. AngioDynamics had a negative net margin of 10.84% and a positive trailing twelve-month return on equity of 0.41%.
View AngioDynamics' earnings history.

AngioDynamics' stock was trading at $10.14 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ANGO stock has increased by 149.6% and is now trading at $25.31.
View which stocks have been most impacted by COVID-19.

AngioDynamics updated its FY 2022 earnings guidance on Tuesday, August, 3rd. The company provided earnings per share (EPS) guidance of $0.000-$0.050 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.070. The company issued revenue guidance of $305 million-$310 million, compared to the consensus revenue estimate of $297.90 million.

3 Wall Street analysts have issued 1-year price targets for AngioDynamics' stock. Their forecasts range from $28.00 to $32.00. On average, they expect AngioDynamics' share price to reach $30.00 in the next twelve months. This suggests a possible upside of 18.5% from the stock's current price.
View analysts' price targets for AngioDynamics or view top-rated stocks among Wall Street analysts.

27 employees have rated AngioDynamics CEO James C. Clemmer on Glassdoor.com. James C. Clemmer has an approval rating of 50% among AngioDynamics' employees. This puts James C. Clemmer in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to AngioDynamics include Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Stryker (SYK), Becton, Dickinson and (BDX), Edwards Lifesciences (EW), Boston Scientific (BSX), IDEXX Laboratories (IDXX), DexCom (DXCM), Baxter International (BAX), ResMed (RMD), STERIS (STE), Insulet (PODD), Hologic (HOLX) and Teleflex (TFX).
View all of ANGO's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other AngioDynamics investors own include General Electric (GE), Intel (INTC), (OAS), Advanced Micro Devices (AMD), Freeport-McMoRan (FCX), Amicus Therapeutics (FOLD), Rigel Pharmaceuticals (RIGL), Accuray (ARAY), Celldex Therapeutics (CLDX) and Chimerix (CMRX).

AngioDynamics trades on the NASDAQ under the ticker symbol "ANGO."

AngioDynamics' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (16.59%), Dimensional Fund Advisors LP (7.37%), Vanguard Group Inc. (6.57%), Victory Capital Management Inc. (6.10%), FMR LLC (5.41%) and State Street Corp (4.90%). Company insiders that own AngioDynamics stock include Dave Helsel, James C Clemmer, Stephen A Trowbridge and Wesley Johnson.
View institutional ownership trends for AngioDynamics.

ANGO stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., BlackRock Inc., State Street Corp, Prudential Financial Inc., Mitsubishi UFJ Kokusai Asset Management Co. Ltd., Bank of America Corp DE, Renaissance Technologies LLC, and Nuveen Asset Management LLC. Company insiders that have sold AngioDynamics company stock in the last year include Dave Helsel, and Wesley Johnson.
View insider buying and selling activity for AngioDynamics or view top insider-selling stocks.

ANGO stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Millennium Management LLC, Frontier Capital Management Co. LLC, FMR LLC, EAM Investors LLC, JPMorgan Chase & Co., Morgan Stanley, and Morgan Stanley. Company insiders that have bought AngioDynamics stock in the last two years include James C Clemmer, and Stephen A Trowbridge.
View insider buying and selling activity for AngioDynamics or or view top insider-buying stocks.

Shares of ANGO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ANGO stock can currently be purchased for approximately $25.31.

AngioDynamics has a market capitalization of $973.02 million and generates $291.01 million in revenue each year. The medical instruments supplier earns $-31,550,000.00 in net income (profit) each year or $0.05 on an earnings per share basis.

AngioDynamics employs 800 workers across the globe.

The following companies are subsidiares of AngioDynamics: AngioDynamics Canada Inc., AngioDynamics France SARL, AngioDynamics Medical Brasil Participacoes Ltda., AngioDynamics Netherlands B. V., AngioDynamics UK Limited, AngioDynamics VA LLC, Clinical Devices, Eximo Medical Ltd., FlowMedica, NM Holding Company Inc., Navilyst Medical Holdings Inc., Navilyst Medical Inc., Oncovionic, RITA Medical Systems, RITA Medical Systems LLC, RadiaDyne LLC, and Vortex Medical.

AngioDynamics was founded in 1988.

The official website for AngioDynamics is www.angiodynamics.com.

AngioDynamics is headquartered at 14 PLAZA DRIVE, LATHAM NY, 12110.

AngioDynamics' mailing address is 14 PLAZA DRIVE, LATHAM NY, 12110. The medical instruments supplier can be reached via phone at (518) 795-1400 or via email at [email protected].